ACP
GOSS icon

Arcus Capital Partners’s Gossamer Bio GOSS Stock Holding History

Arcus Capital Partners’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,042
Closed -$9.16K – 115
2023
Q4 		$9.16K Hold
10,042
– – ﹤0.01% 107
2023
Q3 		$8.36K Buy
+10,042
New +$11.6K ﹤0.01% 125

Other funds holding GOSS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Arcus Capital Partners's GOSS Position: Q1 2024 in Review

Arcus Capital Partners sold out of Gossamer Bio (GOSS) in Q1 2024, closing a stake of 10,042 shares — an estimated $9.16K sold.

Arcus Capital Partners first reported a position in GOSS in Q3 2023 and held it in 2 quarters. The position peaked at $9.16K in Q4 2023. 110 funds tracked by Wall St. Rank hold GOSS as of Q1 2024.

  • Arcus Capital Partners reported no remaining Gossamer Bio position as of Q1 2024 after selling out during the quarter.
  • Arcus Capital Partners sold 10,042 Gossamer Bio shares in Q1 2024, an estimated $9.16K.
  • Arcus Capital Partners first reported a position in Gossamer Bio in Q3 2023 and held it in 2 quarters.
  • Arcus Capital Partners's Gossamer Bio position peaked at $9.16K in Q4 2023.
  • 110 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2024.

Based on Arcus Capital Partners's 13F filing for Q1 2024, filed 19 Apr 2024.